To evaluate the therapeutic impacts of various brands of botulinum toxin A on Meige syndrome, particularly focusing on the accompanying anxiety symptoms.
Key Findings:
No statistically significant differences in overall remission rate and duration of efficacy between Hengli and Botox cohorts (p > 0.05), suggesting similar effectiveness.
No significant variations in anxiety and depression scores, sleep metrics pre- and post-treatment (p > 0.05), indicating comparable impacts on mental health.
No notable differences in adverse effects between the two groups (p > 0.05), highlighting safety across brands.
Interpretation:
Regional administration of botulinum toxin type A is a safe and effective treatment for Meige syndrome with anxiety symptoms, with no significant differences in efficacy among different brands. Patient preferences should also be considered in treatment decisions.
Limitations:
Retrospective design may introduce bias.
Limited sample size for each cohort.
Short follow-up duration may not capture long-term effects.
Potential confounding factors were not controlled.
Conclusion:
Clinical practice should be guided by pragmatic factors when choosing the suitable brand of botulinum toxin type A for treating Meige syndrome with anxiety symptoms, and further research is needed to validate these findings.
